logo
Plus   Neg
Share
Email

NRG Announces Asset Sales Incl. Sale Of Interest In NRG Yield; $2.8 Bln Proceeds

NRG Energy, Inc. (NRG) and Global Infrastructure Partners have entered into a purchase agreement for GIP to purchase NRG's ownership in NRG Yield and NRG's Renewables Platform for cash proceeds of $1.375 billion. NRG and NRG Yield entered into Purchase and Sale Agreements for NRG Yield to purchase NRG's interest in the ROFO pipeline assets: 527 MW Carlsbad Energy Center and 154 MW Buckthorn Solar, for additional cash proceeds of $407 million. NRG and Cleco Corporate Holdings LLC entered into a Purchase and Sale Agreement for Cleco to purchase NRG's South Central business for a total purchase price and cash proceeds of $1.0 billion.

The announcement brings NRG's cumulative Transformation Plan asset sales to $2.9 billion in anticipated cash proceeds, including approximately $150 million of asset monetization closed in the second half of 2017. NRG expects to announce additional asset sales over the course of 2018 and revised its total asset sales cash proceeds target to approximately $3.2 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT